Pacific Biosciences Of California (PACB) Asset Writedowns and Impairment (2022 - 2026)
Pacific Biosciences Of California (PACB) posted quarterly Asset Writedowns and Impairment of $5.2 million for Q4 2025, down 85.58% year-over-year from $36.3 million in Q4 2024, and down 31.69% quarter-over-quarter from $7.7 million in Q1 2025.
Pacific Biosciences Of California (PACB) Asset Writedowns and Impairment (2022 - 2026) Analysis & Trends
Pacific Biosciences Of California's Asset Writedowns and Impairment history runs 4 years deep, the most recent figure standing at $5.2 million for Q4 2025.
- In Q4 2025, Asset Writedowns and Impairment fell 85.58% year-over-year to $5.2 million; the TTM figure through Mar 2026 stood at $5.2 million (down 96.19% YoY), while the FY2025 annual figure was $15.0 million, down 62.5% from the prior year.
- Asset Writedowns and Impairment for Q4 2025 stood at $5.2 million, down from $7.7 million in the prior quarter.
- The five-year high for Asset Writedowns and Impairment was $93.2 million in Q2 2024, with the low at -$4.7 million in Q4 2023.
- The 4-year median for Asset Writedowns and Impairment is $878000.0 (2022), against an average of $11.0 million.
- The sharpest annual moves came in 2024 and 2025: Asset Writedowns and Impairment plunged 99.91% in 2024, then surged 255200.0% in 2025.
- Pacific Biosciences Of California's Asset Writedowns and Impairment stood at -$2.7 million in 2022, then plunged by 75.89% to -$4.7 million in 2023, then jumped by 873.5% to $36.3 million in 2024, then plunged by 85.58% to $5.2 million in 2025.
- Business Quant data shows PACB's Asset Writedowns and Impairment at $5.2 million in Q4 2025, $7.7 million in Q1 2025, and $36.3 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.07 Bn | 193.46 Bn | 7.27 Bn |
| 2 | Stryker | 127.90 Bn | 124.43 Bn | 4.50 Bn |
| 3 | Medtronic | 118.84 Bn | 109.62 Bn | 6.41 Bn |
| 4 | Boston Scientific | 73.33 Bn | 72.79 Bn | 3.85 Bn |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn |
| 6 | Dexcom | 34.46 Bn | 32.51 Bn | 830.00 Mn |
| 7 | GE HealthCare Technologies | 33.91 Bn | 31.81 Bn | 2.18 Bn |
| 8 | Koninklijke Philips | 26.36 Bn | 23.04 Bn | 4.55 Bn |
| 9 | Steris | 23.12 Bn | 22.64 Bn | 684.20 Mn |
| 10 | Pacific Biosciences Of California | 397.64 Mn | 160.77 Mn | 12.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 54,000.00 |
| Mar 31, 2026 | 54,000.00 |
| Dec 31, 2025 | 5.23 Mn |
| Dec 31, 2025 | 5.23 Mn |
| Mar 31, 2025 | 7.66 Mn |
| Mar 31, 2025 | 7.66 Mn |
| Dec 31, 2024 | 36.29 Mn |
| Dec 31, 2024 | 36.29 Mn |
| Jun 30, 2024 | 93.20 Mn |
| Jun 30, 2024 | 93.20 Mn |
| Mar 31, 2024 | 3,000.00 |
| Mar 31, 2024 | 3,000.00 |
| Dec 31, 2023 | -4.69 Mn |
| Dec 31, 2023 | -4.69 Mn |
| Sep 30, 2023 | 396,000.00 |
| Sep 30, 2023 | 396,000.00 |
| Jun 30, 2023 | 774,000.00 |
| Jun 30, 2023 | 774,000.00 |
| Mar 31, 2023 | 3.52 Mn |
| Mar 31, 2023 | 3.52 Mn |